Solvotrin Therapeutics Partners with USL to Launch Active Iron in New Zealand

Solvotrin Therapeutics, the Irish healthcare developer behind Ireland’s #1 iron supplement, has today announced an exclusive partnership with USL to launch Active Iron in New Zealand.

The agreement marks another major milestone in Active Iron’s international expansion, bringing its clinically proven iron technology to New Zealand consumers through USL’s established retail network.

Developed in collaboration with Trinity College Dublin, Active Iron’s patented technology represents a breakthrough in iron supplementation. The unique, groundbreaking formula delivers iron directly to the most active site of absorption, maximising uptake while significantly reducing common side effects such as nausea and constipation, helping to overcome long-standing challenges around iron intolerance and poor absorption.

Active Iron is a leading iron brand across Ireland, Europe, and the United States, trusted by healthcare professionals and consumers alike for its superior tolerability and efficacy. The New Zealand launch reflects Solvotrin Therapeutics’ continued commitment to expanding access to clinically driven health solutions in key global markets.

Through this partnership, USL will lead the commercial rollout of Active Iron across pharmacy and retail channels nationwide, ensuring broad availability for New Zealand consumers seeking a more effective and gentle iron supplement.